Skip to Content


Pfizer Inc.,; Withdrawal of Approval of 12 Abbreviated New Drug Applications

Document Details

Information about this document as published in the Federal Register.

Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document including its time on Public Inspection. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble


Food and Drug Administration, HHS.




The Food and Drug Administration (FDA or Agency) is withdrawing approval of 12 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.


Approval is withdrawn as of July 27, 2020.

Start Further Info


Martha Nguyen, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1676, Silver Spring, MD 20993-0002, 240-402-6980,

End Further Info End Preamble Start Supplemental Information


The applicants listed in the table have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process described in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling.

Application No.DrugApplicant
ANDA 060567Lidocaine Hydrochloride (HCl); Oxytetracycline Injection, 2%; 50 milligrams (mg)/milliters (mL), and 2%; 125 mg/mLPfizer Inc., 235 East 42nd St., New York, NY 10017.
ANDA 062612Gentamicin Sulfate Injection, Equivalent to (EQ) 10 mg base/mLHospira, Inc., 275 North Field Dr., Bldg. H1, Lake Forest, IL 60045.
ANDA 062811Clindamycin Phosphate Solution, EQ 1% baseG&W Laboratories Inc., 301 Helen St., South Plainfield, NJ 07080.
ANDA 063333Cefoperazone Sodium for Injection, EQ 1 gram (gm) base/vialPfizer Inc.
Start Printed Page 38145
ANDA 078288Ondansetron HCl Injection, EQ 2 mg base/mLBaxter Healthcare Corp., 1 Baxter Parkway, Deerfield, IL 60015.
ANDA 080426Hydrocortisone Lotion, 0.5%Bausch Health Americas Inc., 400 Somerset Corporate Blvd., Bridgewater, NJ 08807.
ANDA 090813Levetiracetam Injection, 500 mg/5 mL (100 mg/mL)Fresenius Kabi USA, LLC., Three Corporate Dr., Lake Zurich, IL 60047.
ANDA 201751Articaine HCl; Epinephrine Bitartrate Injection, 4%; EQ 0.0085 mg base/1.7 mL; 4%; EQ 0.005 mg base/mLHansamed Ltd., 4761 Tara Ct., West Bloomfield, MI 48323.
ANDA 202684Levonorgestrel Tablets, 0.75 mgAlvogen PB Research and Development LLC, U.S. Agent for Lotus Pharmaceutical Co., Ltd. Nantou Plant, 44 Whippany Rd., Suite 300, Morristown, NJ 07960.
ANDA 204796Capreomycin Sulfate for Injection, EQ 1 gm base/vialHisun Pharmaceuticals USA, Inc., U.S. Agent for Hisun Pharmaceutical (Hangzhou) Co., Ltd., 200 Crossing Blvd., 2nd Floor, Bridgewater, NJ 08807.
ANDA 205943Ethinyl Estradiol; Levonorgestrel Tablets, 0.02 mg, 0.15 mg; 0.025 mg, 0.15 mg; 0.03 mg, 0.15 mg; 0.01 mg, N/ALupin Pharmaceuticals, Inc., 111 South Calvert St., Baltimore, MD 21202.
ANDA 212191Fluoxetine HCl Tablets, EQ 60 mg baseG&W Laboratories, Inc.

Therefore, approval of the applications listed in the table, and all amendments and supplements thereto, is hereby withdrawn as of July 27, 2020. Approval of each entire application is withdrawn, including any strengths and dosage forms inadvertently missing from the table. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in the table that are in inventory on July 27, 2020, may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first.

Start Signature

Dated: June 19, 2020.

Lowell J. Schiller,

Principal Associate Commissioner for Policy.

End Signature End Supplemental Information

[FR Doc. 2020-13661 Filed 6-24-20; 8:45 am]